© 2020 MJH Life Sciences and AJMC. All rights reserved.
© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
September 15, 2008
Osteoporosis treatment for high-risk women is cost-effective, with bisphosphonates providing the most benefit at the lowest cost.
We estimate the future net tax contributions from an IVF-conceived child to highlight that removing barriers to fertility treatments can have long-term economic benefits.
September 14, 2008
This study analyzes the return on investment for bariatric surgery in the United States.
Diabetes mellitus (DM) prediction equations developed by the Framingham Offspring Study were validated, but the point score underestimated DM risk in an HMO population.
Pharmacoeconomic analyses appear to account for differences in recommendations made regarding public payment when national bodies consider the same drugs for the same indication.
This editorial discusses the cost implication of bariatric surgery and whether or not return on investment analysis should be used to make coverage decisions.
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
LETTERS TO THE EDITORS